A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression The IT-MATTERS Clinical trial - Prognostic role of tumor PD-L1 expression.

Oral OncolJul 31, 2026 (epub)
Clinical ResearchOncology (Medical)Otolaryngology (ENT)

Eyal Talor, Philip Lavin, John Cipriano et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase III randomized controlled trial evaluated the impact of neoadjuvant Leukocyte Interleukin Injection (LI) combined with CIZ on overall survival (OS) in patients with low-risk oral squamous cell carcinoma (OSCC) and soft palate cancer. The study found that patients receiving LI+CIZ+SOC had a superior OS compared to standard of care (SOC), with a hazard ratio of 0.34 (p=0.0012) in the selected cohort.

Key findings

  • Overall survival (OS) was significantly improved with LI+CIZ+SOC compared to SOC, HR 0.64, p=0.0569.
  • In the selected cohort (cN0, PD-L1 TPS <10%), OS reached HR 0.34, p=0.0012.
  • The intention-to-treat low-risk cohort showed an OS HR of 0.26, p=0.0023.
  • Progression-free survival (PFS) also improved, with HR 0.43, p=0.0178.

Why it matters

The findings suggest that incorporating neoadjuvant immunotherapy in low-risk OSCC patients may enhance survival outcomes, challenging current treatment paradigms and potentially improving patient management strategies.

Source

PubMed · PMID 42537452

Published in Oral Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.